Previous studies have questioned the value of thrombophilia testing after VTE. Guidelines have been largely silent on this issue and most expert recommendations stress informed patient preference as a deciding factor.
This systematic review now suggests that the finding of heterozygousity and homozygousity for factor V Leiden in probands and relatives may be predictive. It is debatable whether this finding would lead to treatment change that would improve outcomes. At this time the best we can say is that the decision for testing of hereditary thrombophilia should be individualized.